← Back to Events
ONCOLOGY 24 DAYS AWAY
ASCO
The most important clinical oncology conference in the world, presenting groundbreaking trial results, new treatment paradigms, and major advances in cancer care that shape oncology pipelines.
40,000+ Attendees
Coverage & Analysis
🇺🇸 Latest Americas News
All news → May 5 Palvella Therapeutics Begins Phase 2 Trial of QTORIN Rapamycin for Rare Angiokeratomas May 5 Neurocrine Biosciences Begins Phase 1 Trial of NBIP-2118 for Obesity Treatment May 5 CAPLYTA (Lumateperone) Ranks Highest Among FDA-Approved Adjunctive Depression Treatments in Network Meta-Analysis May 5 Cellenkos Receives FDA Clearance for CK0802 Phase 2a Trial in Steroid-Refractory GVHD May 5 Cellenkos Receives FDA Clearance for CK0802 Phase 1b/2a Trial in Steroid-Refractory GVHD